Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Chemomab Therapeutics, a clinical-stage biotech company focused on fibro-inflammatory diseases, will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023. The conference will be held virtually, with the presentation scheduled for 9:20 am ET. Investors can also request 1-on-1 meetings with management through Oppenheimer representatives. Chemomab is advancing its lead product, CM-101, targeting fibrosis and inflammation. Recent developments include completing a Phase 2 liver fibrosis biomarker study and preparing for a Phase 2 trial in systemic sclerosis in the first half of 2023. More details are available at investors.chemomab.com/events.

TEL AVIV, Israel, March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33^rd Annual Healthcare Conference on Wednesday March 15, 2023. The conference format this year is virtual.

	Oppenheimer 33rd Annual Healthcare Conference
	Format: Presentation Date: Presentation Time: Registration/Webcast:	Virtual corporate update and 1-on-1 investor meetings Wednesday, March 15, 2023 9:20 am ET Click Here

To request a virtual 1-on-1 meeting with Chemomab management, investors should speak with an Oppenheimer representative.

An archived version of the presentation webcast will also be available at the Investor Relations section of the company's website at investors.chemomab.com/events.

About Chemomab Therapeutics

Chemomab is a clinical stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. A Phase 2 liver fibrosis biomarker study in NASH patients was recently completed and a Phase 2 trial in primary sclerosing cholangitis patients is ongoing. Chemomab expects to open a Phase 2 trial in systemic sclerosis for patient enrollment in the first half of 2023. For more information on Chemomab, visit chemomab.com.

Contacts:

Media: Barbara Lindheim   Chemomab Therapeutics Consulting Vice President Investor & Public Relations, Strategic Communications Phone: +1-917-355-9234 barbara@chemomab.com

Investor Relations:  Irina Koffler LifeSci Advisors, LLC  Phone: +1-917-734-7387  ir@chemomab.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference-301762888.html

SOURCE Chemomab Therapeutics

FAQ

What is Chemomab Therapeutics presenting at the Oppenheimer 33rd Annual Healthcare Conference?

Chemomab Therapeutics will present a corporate overview and participate in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023.

When is Chemomab's presentation scheduled during the Oppenheimer conference?

Chemomab's presentation is scheduled for 9:20 am ET on March 15, 2023.

How can investors meet with Chemomab management during the conference?

Investors can request a virtual 1-on-1 meeting with Chemomab management by contacting an Oppenheimer representative.

What recent clinical studies has Chemomab completed?

Chemomab recently completed a Phase 2 liver fibrosis biomarker study in NASH patients.

What future trials is Chemomab planning for CM-101?

Chemomab expects to open a Phase 2 trial in systemic sclerosis for patient enrollment in the first half of 2023.